Ranimustine - Mitsubishi Tanabe PharmaAlternative Names: Cymerin
Latest Information Update: 22 Dec 2015
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Antineoplastics; Nitrosourea compounds
- Mechanism of Action Alkylating agents; DNA cross linking agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Lymphoma